 [1m([0morchestrator-acute liver injury-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ERYTHROMYCIN ETHYLSUCCINATE increase or [0m
[34mdecrease the risk of acute liver injury?[0m
 [1m([0morchestrator-acute liver injury-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-acute liver injury-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ERYTHROMYCIN ETHYLSUCCINATE increase the risk of acute liver injury?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ERYTHROMYCIN ETHYLSUCCINATE increase the risk[0m
[32mof acute liver injury?[0m
 [1m([0morchestrator-acute liver injury-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ERYTHROMYCIN ETHYLSUCCINATE increase the risk of acute liver injury?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ERYTHROMYCIN ETHYLSUCCINATE increase the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"ERYTHROMYCIN ETHYLSUCCINATE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: warnings: WARNINGS Hepatotoxicity There have been reports of hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic [0m
[31mhepatitis, with or without jaundice, occurring in patients receiving oral erythromycin products. QT Prolongation Erythromycin has been associated with prolongation of the QT interval and infrequent [0m
[31mcases of arrhythmia. Cases of torsades de pointes have been spontaneously reported during postmarketing surveillance in patients receiving erythromycin. Fatalities have been reported. Erythromycin [0m
[31mshould be avoided in patients with known prolongation of the QT interval, patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant [0m
[31mbradycardia, and in patients receiving Class IA [0m[1;31m([0m[31mquinidine, procainamide[0m[1;31m)[0m[31m or Class III [0m[1;31m([0m[31mdofetilide, amiodarone, sotalol[0m[1;31m)[0m[31m antiarrhythmic agents. ERYTHROMYCIN ETHYLSUCCINATE: warnings: Elderly patients [0m
[31mmay be more susceptible to drug-associated effects on the QT interval. Syphilis in Pregnancy There have been reports suggesting that erythromycin does not reach the fetus in adequate concentration to [0m
[31mprevent congenital syphilis. Infants born to women treated during pregnancy with oral erythromycin for early syphilis should be treated with an appropriate penicillin regimen. Clostridium difficile [0m
[31mAssociated Diarrhea Clostridium difficile associated diarrhea [0m[1;31m([0m[31mCDAD[0m[1;31m)[0m[31m has been reported with use of nearly all antibacterial agents, including Ery-Ped, and may range in severity from mild diarrhea to [0m
[31mfatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile . C. difficile produces toxins A and B which contribute to the development[0m
[31mof CDAD. Hypertoxin producing strains of C. ERYTHROMYCIN ETHYLSUCCINATE: warnings: difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and[0m
[31mmay require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two [0m
[31mmonths after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and [0m
[31melectrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated. Drug Interactions Serious adverse reactions[0m
[31mhave been reported in patients taking erythromycin concomitantly with CYP3A4 substrates. These include colchicine toxicity with colchicine; rhabdomyolysis with simvastatin, lovastatin, and [0m
[31matorvastatin; and hypotension with calcium channel blockers metabolized by CYP3A4 [0m[1;31m([0m[31me.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: adverse_reactions: ADVERSE REACTIONS The most frequent side effects of oral erythromycin preparations are gastrointestinal and are dose-related. They include [0m
[31mnausea, vomiting, abdominal pain, diarrhea and anorexia. Symptoms of hepatitis, hepatic dysfunction and/or abnormal liver function test results may occur. [0m[1;31m([0m[31mSee WARNINGS section.[0m[1;31m)[0m[31m Onset of [0m
[31mpseudomembranous colitis symptoms may occur during or after antibacterial treatment. [0m[1;31m([0m[31mSee WARNINGS .[0m[1;31m)[0m[31m Erythromycin has been associated with QT prolongation and ventricular arrhythmias, including [0m
[31mventricular tachycardia and torsades de pointes. [0m[1;31m([0m[31mSee WARNINGS .[0m[1;31m)[0m[31m Allergic reactions ranging from urticaria to anaphylaxis have occurred. Skin reactions ranging from mild eruptions to erythema [0m
[31mmultiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported rarely. There have been reports of interstitial nephritis coincident with erythromycin use. ERYTHROMYCIN [0m
[31mETHYLSUCCINATE: adverse_reactions: There have been rare reports of pancreatitis and convulsions. There have been isolated reports of reversible hearing loss occurring chiefly in patients with renal [0m
[31minsufficiency and in patients receiving high doses of erythromycin.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: clinical_pharmacology: CLINICAL PHARMACOLOGY Orally administered erythromycin ethylsuccinate suspension is readily and reliably absorbed under both fasting and [0m
[31mnonfasting conditions. Erythromycin diffuses readily into most body fluids. Only low concentrations are normally achieved in the spinal fluid, but passage of the drug across the blood-brain barrier [0m
[31mincreases in meningitis. In the presence of normal hepatic function, erythromycin is concentrated in the liver and excreted in the bile; the effect of hepatic dysfunction on excretion of erythromycin [0m
[31mby the liver into the bile is not known. Less than [0m[1;31m5[0m[31m percent of the orally administered dose of erythromycin is excreted in active form in the urine. Erythromycin crosses the placental barrier, but [0m
[31mfetal plasma levels are low. The drug is excreted in human milk. ERYTHROMYCIN ETHYLSUCCINATE: microbiology: Microbiology Mechanism of Action Erythromycin acts by inhibition of protein synthesis by [0m
[31mbinding [0m[1;31m50[0m[31m S ribosomal subunits of susceptible organisms. It does not affect nucleic acid synthesis. Antagonism has been demonstrated in vitro between erythromycin and clindamycin, lincomycin, and [0m
[31mchloramphenicol. Resistance Many strains of Haemophilus influenzae are resistant to erythromycin alone but are susceptible to erythromycin and sulfonamides used concomitantly. Interactions With Other [0m
[31mAntimicrobials Staphylococci resistant to erythromycin may emerge during a course of therapy. Antimicrobial Activity Erythromycin has been shown to be active against most strains of the following [0m
[31mmicroorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section. ERYTHROMYCIN ETHYLSUCCINATE: microbiology: Gram-positive Organisms: Corynebacterium [0m
[31mdiphtheriae Corynebacterium minutissimum Listeria monocytogenes Staphylococcus aureus [0m[1;31m([0m[31mresistant organisms may emerge during treatment[0m[1;31m)[0m[31m Streptococcus pneumoniae Streptococcus pyogenes Gram-negative [0m
[31mOrganisms: Bordetella pertussis Legionella pneumophila Neisseria gonorrhoeae Other Microorganisms: Chlamydia trachomatis Entamoeba histolytica Mycoplasma pneumoniae Treponema pallidum Ureaplasma [0m
[31murealyticum The following in vitro data are available. Erythromycin exhibits in vitro minimal inhibitory concentrations [0m[1;31m([0m[31mMIC's[0m[1;31m)[0m[31m of [0m[1;31m0[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: spl_product_data_elements: Ery-Ped Erythromycin Ethylsuccinate CARAMEL POLYSORBATE [0m[1;31m80[0m[31m SODIUM CITRATE, UNSPECIFIED FORM SUCROSE XANTHAN GUM ERYTHROMYCIN [0m
[31mETHYLSUCCINATE ERYTHROMYCIN Ery-Ped Erythromycin Ethylsuccinate CARAMEL POLYSORBATE [0m[1;31m80[0m[31m SODIUM CITRATE, UNSPECIFIED FORM SUCROSE XANTHAN GUM ERYTHROMYCIN ETHYLSUCCINATE ERYTHROMYCIN         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: brand_name         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: generic_name         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: package_ndc         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: drug_interactions: Hypotension, bradyarrhythmias, and lactic acidosis have been observed in patients receiving concurrent verapamil, belonging to the calcium [0m
[31mchannel blockers drug class. Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels. There have been reports of increased anticoagulant [0m
[31meffects when erythromycin and oral anticoagulants were used concomitantly. Increased anticoagulation effects due to interactions of erythromycin with various oral anticoagulants may be more pronounced[0m
[31min the elderly. Erythromycin is a substrate and inhibitor of the 3A isoform subfamily of the cytochrome p450 enzyme system [0m[1;31m([0m[31mCYP3A[0m[1;31m)[0m[31m. ERYTHROMYCIN ETHYLSUCCINATE: drug_interactions: Coadministration of [0m
[31merythromycin and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both the therapeutic and adverse effects of the [0m
[31mconcomitant drug. Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored closely in patients concurrently receiving [0m
[31merythromycin. The following are examples of some clinically significant CYP3A based drug interactions. Interactions with other drugs metabolized by the CYP3A isoform are also possible. ERYTHROMYCIN [0m
[31mETHYLSUCCINATE: drug_interactions: The following CYP3A based drug interactions have been observed with erythromycin products in post-marketing experience: Ergotamine/dihydroergotamine Post-marketing [0m
[31mreports indicate that co-administration of erythromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterized by vasospasm and ischemia of the extremities [0m
[31mand other tissues including the central nervous system. Concomitant administration of erythromycin with ergotamine or dihydroergotamine is contraindicated [0m[1;31m([0m[31msee CONTRAINDICATIONS [0m[1;31m)[0m[31m. [0m
[31mTriazolobenzodiazepines [0m[1;31m([0m[31msuch as triazolam and alprazolam[0m[1;31m)[0m[31m and Related Benzodiazepines Erythromycin has been reported to decrease the clearance of triazolam and midazolam, and thus, may increase the [0m
[31mpharmacologic effect of these benzodiazepines. ERYTHROMYCIN ETHYLSUCCINATE: drug_interactions: HMG-CoA Reductase Inhibitors Erythromycin has been reported to increase concentrations of HMG-CoA [0m
[31mreductase inhibitors [0m[1;31m([0m[31me.g., lovastatin and simvastatin[0m[1;31m)[0m[31m. Rare reports of rhabdomyolysis have been reported in patients taking these drugs concomitantly. Sildenafil [0m[1;31m([0m[31mViagra[0m[1;31m)[0m[31m Erythromycin has been [0m
[31mreported to increase the systemic exposure [0m[1;31m([0m[31mAUC[0m[1;31m)[0m[31m of sildenafil. Reduction of sildenafil dosage should be considered. [0m[1;31m([0m[31mSee Viagra package insert.[0m[1;31m)[0m[31m There have been spontaneous or published reports of [0m
[31mCYP3A based interactions of erythromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine, and bromocriptine. [0m
[31mERYTHROMYCIN ETHYLSUCCINATE: drug_interactions: Concomitant administration of erythromycin with cisapride, pimozide, astemizole, or terfenadine is contraindicated. [0m[1;31m([0m[31mSee CONTRAINDICATIONS .[0m[1;31m)[0m[31m In [0m
[31maddition, there have been reports of interactions of erythromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate. Erythromycin has been reported to[0m
[31msignificantly alter the metabolism of the nonsedating antihistamines terfenadine and astemizole when taken concomitantly. Rare cases of serious cardiovascular adverse events, including [0m
[31melectrocardiographic QT/QT c interval prolongation, cardiac arrest, torsades de pointes, and other ventricular arrhythmias have been observed. [0m[1;31m([0m[31mSee CONTRAINDICATIONS .[0m[1;31m)[0m[31m In addition, deaths have been [0m
[31mreported rarely with concomitant administration of terfenadine and erythromycin.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: information_for_patients: Information for Patients Patients should be counseled that antibacterial drugs including Ery-Ped should only be used to treat bacterial [0m
[31minfections. They do not treat viral infections [0m[1;31m([0m[31me.g., the common cold[0m[1;31m)[0m[31m. When Ery-Ped is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better [0m
[31mearly in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m decrease the effectiveness of the immediate [0m
[31mtreatment and [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m increase the likelihood that bacteria will develop resistance and will not be treatable by Ery-Ped or other antibacterial drugs in the future. Diarrhea is a common problem caused by [0m
[31mantibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools [0m[1;31m([0m[31mwith or without stomach cramps [0m
[31mand fever[0m[1;31m)[0m[31m even as late as two or more months after having taken the last dose of the antibiotic. ERYTHROMYCIN ETHYLSUCCINATE: information_for_patients: If this occurs, patients should contact their [0m
[31mphysician as soon as possible.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: general_precautions: General Prescribing Ery-Ped in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to [0m
[31mprovide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Since erythromycin is principally excreted by the liver, caution should be exercised when [0m
[31merythromycin is administered to patients with impaired hepatic function. [0m[1;31m([0m[31mSee CLINICAL PHARMACOLOGY and WARNINGS sections.[0m[1;31m)[0m[31m Exacerbation of symptoms of myasthenia gravis and new onset of symptoms of [0m
[31mmyasthenic syndrome has been reported in patients receiving erythromycin therapy. There have been reports of infantile hypertrophic pyloric stenosis [0m[1;31m([0m[31mIHPS[0m[1;31m)[0m[31m occurring in infants following erythromycin [0m
[31mtherapy. ERYTHROMYCIN ETHYLSUCCINATE: general_precautions: In one cohort of [0m[1;31m157[0m[31m newborns who were given erythromycin for pertussis prophylaxis, seven neonates [0m[1;31m([0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m developed symptoms of non-bilious [0m
[31mvomiting or irritability with feeding and were subsequently diagnosed as having IHPS requiring surgical pyloromyotomy . A possible dose-response effect was described with an absolute risk of IHPS of [0m
[1;31m5.1[0m[31m% for infants who took erythromycin for [0m[1;31m8[0m[31m-[0m[1;31m14[0m[31m days and [0m[1;31m10[0m[31m% for infants who took erythromycin for [0m[1;31m15[0m[31m-[0m[1;31m21[0m[31m days. [0m[1;31m2[0m[31m Since erythromycin may be used in the treatment of conditions in infants which are [0m
[31massociated with significant mortality or morbidity [0m[1;31m([0m[31msuch as pertussis or neonatal Chlamydia trachomatis infections[0m[1;31m)[0m[31m, the benefit of erythromycin therapy needs to be weighed against the potential risk [0m
[31mof developing IHPS. Parents should be informed to contact their physician if vomiting or irritability with feeding occurs. ERYTHROMYCIN ETHYLSUCCINATE: general_precautions: Prolonged or repeated use [0m
[31mof erythromycin may result in an overgrowth of nonsusceptible bacteria or fungi. If superinfection occurs, erythromycin should be discontinued and appropriate therapy instituted. When indicated, [0m
[31mincision and drainage or other surgical procedures should be performed in conjunction with antibiotic therapy. Observational studies in humans have reported cardiovascular malformations after exposure[0m
[31mto drug products containing erythromycin during early pregnancy. ERYTHROMYCIN ETHYLSUCCINATE: precautions: PRECAUTIONS General Prescribing Ery-Ped in the absence of a proven or strongly suspected [0m
[31mbacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. Since erythromycin is principally [0m
[31mexcreted by the liver, caution should be exercised when erythromycin is administered to patients with impaired hepatic function. [0m[1;31m([0m[31mSee CLINICAL PHARMACOLOGY and WARNINGS sections.[0m[1;31m)[0m[31m Exacerbation of [0m
[31msymptoms of myasthenia gravis and new onset of symptoms of myasthenic syndrome has been reported in patients receiving erythromycin therapy. There have been reports of infantile hypertrophic pyloric [0m
[31mstenosis [0m[1;31m([0m[31mIHPS[0m[1;31m)[0m[31m occurring in infants following erythromycin therapy. ERYTHROMYCIN ETHYLSUCCINATE: precautions: Prolonged or repeated use of erythromycin may result in an overgrowth of nonsusceptible [0m
[31mbacteria or fungi. If superinfection occurs, erythromycin should be discontinued and appropriate therapy instituted. When indicated, incision and drainage or other surgical procedures should be [0m
[31mperformed in conjunction with antibiotic therapy. Observational studies in humans have reported cardiovascular malformations after exposure to drug products containing erythromycin during early [0m
[31mpregnancy. Information for Patients Patients should be counseled that antibacterial drugs including Ery-Ped should only be used to treat bacterial infections. They do not treat viral infections [0m[1;31m([0m[31me.g.,[0m
[31mthe common cold[0m[1;31m)[0m[31m. When Ery-Ped is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be [0m
[31mtaken exactly as directed.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Yes, ERYTHROMYCIN ETHYLSUCCINATE can increase the risk of acute liver injury. There have been reports of hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or [0m
[32mcholestatic hepatitis, with or without jaundice, in patients receiving oral erythromycin products.[0m

[32mSOURCE: ERYTHROMYCIN ETHYLSUCCINATE label[0m
[32mEXTRACT_START_END: [0m[32m...[0m[32mincluding increased liver enzymes, and hepatocellular and/or cholestatic hepatitis[0m[32m...[0m
*[1m([0morchestrator-acute liver injury-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Yes, ERYTHROMYCIN ETHYLSUCCINATE can [0m
[34mincrease the risk of acute liver injury. There have been reports of hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, [0m
[34min patients receiving oral erythromycin products.[0m

[34mSOURCE: ERYTHROMYCIN ETHYLSUCCINATE label[0m
[34mEXTRACT_START_END: [0m[34m...[0m[34mincluding increased liver enzymes, and hepatocellular and/or cholestatic hepatitis[0m[34m...[0m
 [1m([0morchestrator-acute liver injury-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-acute liver injury-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does ERYTHROMYCIN ETHYLSUCCINATE increase or decrease the risk of acute liver injury?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether ERYTHROMYCIN ETHYLSUCCINATE increases the risk of acute liver injury."[0m[32m,[0m
[32m      [0m[32m"FDAHandler confirmed that ERYTHROMYCIN ETHYLSUCCINATE can increase the risk of acute liver injury, citing reports of hepatic dysfunction, including increased liver enzymes, and hepatocellular [0m
[32mand/or cholestatic hepatitis, with or without jaundice, in patients receiving oral erythromycin products."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"ERYTHROMYCIN ETHYLSUCCINATE can increase the risk of acute liver injury."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-acute liver injury-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-acute liver injury-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-acute liver injury-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-acute liver injury-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does ERYTHROMYCIN ETHYLSUCCINATE increase or decrease the risk of acute liver injury?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether ERYTHROMYCIN ETHYLSUCCINATE increases the risk of acute liver injury."[0m[34m,[0m
[34m      [0m[34m"FDAHandler confirmed that ERYTHROMYCIN ETHYLSUCCINATE can increase the risk of acute liver injury, citing reports of hepatic dysfunction, including increased liver enzymes, and hepatocellular [0m
[34mand/or cholestatic hepatitis, with or without jaundice, in patients receiving oral erythromycin products."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"ERYTHROMYCIN ETHYLSUCCINATE can increase the risk of acute liver injury."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does ERYTHROMYCIN ETHYLSUCCINATE increase or decrease the risk of acute liver injury?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether ERYTHROMYCIN ETHYLSUCCINATE increases the risk of acute liver injury.[0m
[1;31m2[0m[31m. FDAHandler confirmed that ERYTHROMYCIN ETHYLSUCCINATE can increase the risk of acute liver injury, citing reports of hepatic dysfunction, including increased liver enzymes, and hepatocellular [0m
[31mand/or cholestatic hepatitis, with or without jaundice, in patients receiving oral erythromycin products.[0m
[31m        -----[0m
[31m        Final answer: ERYTHROMYCIN ETHYLSUCCINATE can increase the risk of acute liver injury.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-acute liver injury-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-acute liver injury-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was [0m
[31mprovided.[0m
 [1m([0morchestrator-acute liver injury-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-acute liver injury-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-acute liver injury-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mERYTHROMYCIN ETHYLSUCCINATE can increase the risk of acute liver injury. This is based on reports of hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic [0m
[32mhepatitis, with or without jaundice, in patients receiving oral erythromycin products, as confirmed by FDAHandler using the ERYTHROMYCIN ETHYLSUCCINATE label.[0m
